SINGAPORE, Dec. 10 /PRNewswire/ -- S*BIO Pte Ltd today announced the data presentation on its most advanced compounds at The American Society of Hematology 49th Annual Meeting and Exposition in Atlanta, Georgia. An oral presentation made on its novel and selective JAK2 inhibitor SB1518 highlighted the therapeutic potential of SB1518 for the treatment of myeloproliferative disorders.
In addition, a poster was presented on S*BIO’s orally-active “best-in- class” HDAC inhibitor SB939 detailing its therapeutic potential for the treatment of hematological malignancies while a poster on S*BIO’s novel kinase inhibitor SB1317 showed data for the potential treatment of acute leukemias.
“We are pleased to announce data for the first time on our JAK2 inhibitor, SB1518, and its potential treatment of myeloproliferative disorders, an area of great unmet medical need,” said Dr. Jan-Anders Karlsson, CEO of S*BIO. “We are currently conducting Phase I clinical trials for SB939 in Canada and Singapore, and expect the initiation of Phase I trials in various centers in the U.S. We are also delighted to report data on our Flt3-CDK inhibitor, SB1317. The data presented clearly demonstrate the strength and diversity of S*BIO’s pipeline and validate our target-driven approach in developing ‘best-in-class’ and ‘first-in-class’ drugs.”
Oral Presentation (Session: Molecular Pharmacology -- Novel Therapies I)
SB1518: A potent and orally-active JAK2 Inhibitor for the treatment of myeloproliferative disorders
SB1518, a potent ATP-competitive inhibitor of both JAK2 kinase, and its JAK2V617F mutant, demonstrated therapeutic potential for the treatment of myeloproliferative disorders caused by aberrant JAK2 signaling. JAK2 is the most common mutated gene in bcr-abl-negative chronic myeloproliferative disorders (MPDs).
Poster No. 757
SB939: A potent and orally-active HDAC inhibitor for the treatment of hematological malignancies
SB939, a novel histone deacetylase HDAC inhibitor with improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors, is currently in Phase I clinical trials, and has demonstrated potential for the treatment of various types of hematological malignancies.
Poster No. 747
SB1317, a potent and orally-active FLT3-CDK inhibitor with high anti-tumor efficacy in models of hematological malignancies
SB1317, a novel potent inhibitor of FLT3 kinase and CDKs 1, 2 and 9, demonstrated therapeutic potential for the treatment of hematological malignancies. FLT3 is the most common mutated gene in acute myeloid leukemia
(AML), and CDK1, 2, and 9 are well-established anti-cancer targets due to their direct role in cell cycle control.
About S*BIO Pte Ltd
S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO’s lead candidate, SB939, has entered the clinic in 2Q 2007. It recently announced that a second compound, SB1518, would enter the clinic in 1H 2008 and that a third compound, SB1317, is in pre-clinical development.
In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong linkages with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Novartis Bioventures and other international funds. More information about S*BIO can be found at www.sbio.com.
Stephen_rhind@sbio.comTony.Russo@russopartnersllc.comAndreas.Marathis@russopartnersllc.com
CONTACT: Stephen Keith Rhind, Ph.D., Senior Vice President of Corporate
Development at S*BIO Pte Ltd, +65-6827-5000 (Singapore),
Stephen_rhind@sbio.com; or Tony Russo +1-212-845-4251,
Tony.Russo@russopartnersllc.com, or Andreas Marathovouniotis
+1-212-845-4253, Andreas.Marathis@russopartnersllc.com, both of Russo
Partners for S*BIO Pte Ltd
Web site: http://www.sbio.com/
